ClinicalTrials.gg
CompletedNCT06159452Updated Dec 6, 2023

Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects

A Phase 1 interventional study of SAR153191-P3 drug product and SAR153191-P2 drug product in Rheumatoid Arthritis, sponsored by Sanofi. Completed. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2010, 15 years 10 months ago, and no results have been posted to the registry.
  • Registered 13 years 4 months after the study started (first participant enrolled Jul 2010, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
14th of 22
53 · median 88
Started
2010
with 3 others
Phase 1
7 of 22
none open now
Registered
21st of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 14th largest by enrollment, is one of 4 that started in 2010, is one of 7 in phase 1, and was the 21st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary objective:

To determine the tolerability of different SAR153191 drug products that differ with respect to manufacturing processes and formulation, at different concentrations and doses, after administration of single subcutaneous doses to healthy male subjects.

Secondary objectives:

To determine the pharmacokinetic profile of the different SAR153191 drug products administered subcutaneously.

To assess the safety of the different SAR153191 drug products administered subcutaneously.

Read the detailed description

Up to 35 Days

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Having given written prior to any procedure related to the study. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
  • Any subject who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Group A

    SAR153191 - P3 drug product concentration 1 dose 1

    Drug: SAR153191-P3 drug product

  • Experimental
    Group B

    SAR153191 - P2 drug product concentration 2 dose 2

    Drug: SAR153191-P2 drug product

  • Experimental
    Group C

    SAR153191 - P3 drug product concentration 2 dose 2

    Drug: SAR153191-P3 drug product

  • Experimental
    Group D

    SAR153191 - P3 drug product concentration 3 dose 3

    Drug: SAR153191-P3 drug product

  • Experimental
    Group B'

    SAR153191 - P2 drug product concentration 2 dose 3

    Drug: SAR153191-P2 drug product

  • Experimental
    Group C'

    SAR153191 - P3 drug product concentration 2 dose 3

    Drug: SAR153191-P3 drug product

  • Active comparator
    Group E'

    SAR153191 - CIF3 drug product concentration 2 dose 3

    Drug: SAR153191-C1F3 drug product

Interventions

  • Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

    Also known as: SAR153191

  • Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

    Also known as: SAR153191

  • Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection

    Also known as: SAR153191

06

What researchers measure

Primary outcomes

  1. Number of participants reporting injection site reactions

    Injection site reactions include pain, erythema an edema.

    Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21, and 35 following SAR153191 administration

Secondary outcomes

  1. Pharmacokinetics: Cmax

    Maximum plasma concentration observed

    Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration

  2. Pharmacokinetics: tmax

    First time to reach Cmax

    Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration

  3. Pharmacokinetics: AUClast

    Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time

    Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration

  4. Pharmacokinetics: AUC

    Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration

  5. Pharmacokinetics: t1/2z

    Terminal half-life associated with the terminal slope (λz)

    Time frame: At predose and on Days 1, 2, 3, 4, 5, 7, 9, 11, 14, 21 and 35 following SAR153191 administration

  6. Safety: Number of participants who experienced Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment-Emergent Adverse Events of Special Interest (AESI)

    Time frame: Up to 35 Days

  7. Incidence of anti-SAR153191 antibodies

    Time frame: At Day 1 predose and on Days 7, 21, and 35 (plus follow-up if positive)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2010 to primary completion in Dec 2010, 5 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 5 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2023
First posted
Dec 6, 2023
StartActual
Jul 9, 2010
Primary completionActual
Dec 21, 2010
CompletionActual
Dec 21, 2010
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06159452
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
Jul 9, 2010
Primary completion
Dec 21, 2010
Completion
Dec 21, 2010
Last update
Dec 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarilumab

Start the discussion